Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Status: Recruiting

Conditions: Sarcoidosis

Location:

aTyr Investigative Site

City/State:

Birmingham, Alabama

Los Angeles, California

Newport Beach, California

Valencia, California

Denver, Colorado

Gainesville, Florida

Tampa, Florida

Atlanta, Georgia

Chicago, Illinois

Kansas City, Kansas

Louisville, Kentucky

New Orleans, Louisiana

Baltimore, Maryland

Boston, Massachusetts

Ada, Michigan

Detroit, Michigan

Royal Oak, Michigan

Minneapolis, Minnesota

Rochester, Minnesota

Jackson, Mississippi

Saint Louis, Missouri

Albany, New York

Durham, North Carolina

Greenville, North Carolina

Cincinnati, Ohio

Cleveland, Ohio

Oklahoma City, Oklahoma

Portland, Oregon

Charleston, South Carolina

Dickson, Tennessee

Nashville, Tennessee

Dallas, Texas

Houston, Texas

Salt Lake City Utah

Falls Church, Virginia

Richmond, Virginia

Contact Information:

aTyr Pharma Clinical Research
877-215-5731
[email protected]

Brief Summary:

This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

You May Also Like

Honoring Mark Austry

MYOCARDITIS AWARENESS DAYS

Contact Us

Social Media

Help Us End Suffering and Sudden Death from Myocarditis!